SCHEMBL19686567

SCHEMBL19686567

Cc1cccc(C)c1OC/C(=N/OCc1ccccc1)C1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
POLB P06746 2/20 0.44
HSP90AA1 P07900 1/20 0.44
MEN1 O00255 1/20 0.44
PTGIR P43119 1/20 0.40
HTR1A P08908 2/20 0.40
ADRA1D P25100 2/20 0.40
ADRA1A P35348 2/20 0.40
ADRA1B P35368 2/20 0.40
SCN4A P35499 1/20 0.38
PTGER4 P35408 2/20 0.38
PTGER3 P43115 2/20 0.38
PTGER2 P43116 2/20 0.38
SCN8A Q9UQD0 1/20 0.37
PTGER1 P34995 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 1/20 0.36
LIPE Q05469 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393854 0.80 KMT2A (0.50) KMT2AL3MBTL1PTGIRHTR1AADRA1D
SCHEMBL2393850 0.80 KMT2A (0.50) KMT2AL3MBTL1PTGIRHTR1AADRA1D
SCHEMBL2397111 0.79 KMT2A (0.49) KMT2AL3MBTL1MEN1HTR1AADRA1D
SCHEMBL21325442 0.79 KMT2A (0.49) KMT2AL3MBTL1MEN1HTR1AADRA1D
SCHEMBL2397115 0.79 KMT2A (0.49) KMT2AL3MBTL1MEN1HTR1AADRA1D
SCHEMBL2390937 0.73 KMT2A (0.44) KMT2AL3MBTL1POLBMEN1HTR1A
SCHEMBL2390933 0.73 KMT2A (0.44) KMT2AL3MBTL1POLBMEN1HTR1A
SCHEMBL2395052 0.73 NPC1 (0.46) KMT2AL3MBTL1HTR1AADRA1DADRA1A
SCHEMBL2395055 0.73 NPC1 (0.46) KMT2AL3MBTL1HTR1AADRA1DADRA1A
SCHEMBL18716386 0.70 HTR1A (0.61) KMT2AL3MBTL1POLBHTR1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2019-09-05 US disclosed
WO-2017210371-A2 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270696-A1 COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS SCN1B, CACNA1E, SCN2B KMT2A 4124/4885L3MBTL1 1336/4885POLB 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.